Craniopharyngioma clinical trials at UCSF

1 in progress, 0 open to eligible people

Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Sorry, not yet accepting patients
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
San Francisco, California

Our lead scientists for Craniopharyngioma research studies include Sabine Mueller, MD, PhD, MAS.

Last updated: July 15, 2022

Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults